The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double-masked study

Clinical Therapeutics

Volumn 18, Issue 5, 1996, Pages 853-863

  Heinonen, Therese M ^a   Stein, Evan ^b   Weiss, Stuart R ^c   McKenney, James M ^d   Davidson, Michael ^e   Shurzinske, Linda ^a   Black, Donald M ^a  

^a PFIZER INC   (United States)

^b Med Res Laboratories International   (United States)

^c S Diego Endocr and Medical Clinic   (United States)

^d Richmond Memorial Hospital   (United States)

^e RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEW DRUG; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; UNITED STATES;

EID: 0029857765     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80045-2     Document Type: Article

References (23)

1. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death: The Framingham study. Arch Intern Med. 1981;141:1128-1131.
2. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study. JAMA. 1986;256:2835-2838.
3. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? Findings in 356,222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256:2823-2828.
4. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 Years of follow-up from the Framingham study. JAMA. 1987;257:2176-2180.
5. Lipid Research Clinics Program. The Lipid Research Clinics Primary Prevention Trial results I: Reduction in incidence of coronary heart disease. JAMA. 1984; 251:351-364.
6. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82: 1916-1924.
7. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
8. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of extensive lipid-lowering therapy in men with high levels of apolipoprotein B. NEJM. 1990;323:1289-1298.
9. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992; 339:563-569.
10. Austin MA. Plasma triglycerides and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
11. Gordon DJ, Probstfeld JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation. 1989; 79:8-15.
12. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta migrating high-density lipoprotein. Biochemistry. 1988;27:25-29.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
14. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
15. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15: 678-682.
16. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics methodology. J Clin Chem Clin Biochem. 1981; 19:850.
17. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 1978;19:67-76.
18. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultra-centrifuge. Clin Chem. 1972;18:499-502.
19. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9: 105-135.
20. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry Standardization Project for Measurements of Apolipoproteins A-1 and B-II: Evaluation and selection of candidate reference materials. Clin Chem. 1992;38: 658-662.
21. Feskanich D, Buzzard IM, Welch BT, et al. Comparison of a computerized and manual method of food coding for nutrient intake studies. J Am Diet Assoc. 1988; 88:1263-1267.
22. Heinonen T, Schrott H, McKenney J, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Ther. 1996;1:117-122.
23. Black D. Atorvastatin: A step ahead for HMG-CoA reductase inhibitors. Atherosclerosis. 1994;190:88.